Top

Published in:

01-09-2018 | Original Article

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve

Authors: Paola Alberti, Emanuela Rossi, Andreas A. Argyriou, Haralabos P. Kalofonos, Chiara Briani, Mario Cacciavillani, Marta Campagnolo, Jordi Bruna, Roser Velasco, Marina E. Cazzaniga, Diego Cortinovis, Maria G. Valsecchi, Guido Cavaletti

Published in: Supportive Care in Cancer | Issue 9/2018

Abstract

Purpose

We aimed to verify the predictiveness of dorsal sural nerve neurophysiological monitoring in obtaining risk stratification for oxaliplatin-induced peripheral neurotoxicity (OXAPN).

Methods

We conducted a secondary analysis on a cohort of 110 colorectal cancer patients who were evaluated clinically and neurophysiologically before chemotherapy, at mid-treatment and at discontinuation. We applied the classification tree analysis method to predict the end-of-treatment OXAPN neurophysiological diagnosis, using data recorded at mid-treatment. We then ascertained the correlation between the obtained classes and neurological impairment at the end of treatment (Fisher’s exact test).

Results

Dorsal sural nerve monitoring enabled us to stratify oxaliplatin-treated patients into risk classes with an implemented approach to neurophysiology application in this setting. Neurological outcome at discontinuation was predicted by neurophysiological monitoring performed during chemotherapy administration.

Conclusions

We demonstrated the role that neurophysiology may play in clinical trials as an early surrogate marker that can predict OXAPN development at the end of treatment. Specifically, we propose abnormal dorsal sural sensory nerve testing as an early biomarker in identifying patients at high risk of eventually developing OXAPN.

Available only for authorised users

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefPubMed

Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, Bergamo F, Cortinovis D, Cazzaniga M, Bruna J, Cavaletti G, Kalofonos HP (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst 19:299–306CrossRefPubMed

Cavaletti G, Alberti P, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book 35:e553–e560CrossRef

Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46CrossRefPubMed

Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367CrossRefPubMedPubMedCentral

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967CrossRefPubMed

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479–494CrossRefPubMed

Alberti P (2017) Chemotherapy-induced peripheral neurotoxicity—outcome measures: the issue. Expert Opin Drug Metab Toxicol 13:241–243CrossRefPubMed

Gewandter JS, Freeman R, Kitt RA, Cavaletti G, Gauthier LR, McDermott MP, Mohile NA, Mohlie SG, Smith AG, Tejani MA, Turk DC, Dworkin RH (2017) Chemotherapy-induced peripheral neuropathy clinical trials: review and recommendations. Neurology 89:859–869CrossRefPubMed

10.

Department of Health and Human Services FaDA (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims

11.

Department of Health and Human Services FaDA (2014) Guidance for industry and FDA staff: qualification process for drug development tools

12.

Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13:492–504CrossRefPubMed

13.

Gewandter JS, Dworkin RH, Finnerup NB, Mohile NA (2017) Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology? Pain 158:30–33CrossRefPubMed

14.

Kerckhove N, Pereira B, Pezet D, Balayssac D (2017) Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint. Pain 158:180–182CrossRefPubMed

15.

Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23:3116–3122CrossRefPubMed

16.

Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999) Total neuropathy score: validation and reliability study. Neurology 53:1660–1664CrossRefPubMed

17.

Cavaletti G, Cornblath DR, Merkies IS et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454–462CrossRefPubMed

18.

Frigeni B, Cacciavillani M, Ermani M, Briani C, Alberti P, Ferrarese C, Cavaletti G (2012) Neurophysiological examination of dorsal sural nerve. Muscle Nerve 46:895–898CrossRefPubMed

19.

Cavaletti G, Bogliun G, Marzorati L, Marzola M, Pittelli MR, Tredici G (1991) The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J Neurol 238:371–374CrossRefPubMed

20.

Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev (3):CD005228. https://doi.org/10.1002/14651858.CD005228.pub4

21.

Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005CrossRefPubMed

22.

Burke D, Skuse NF, Lethlean AK (1974) Sensory conduction of the sural nerve in polyneuropathy. J Neurol Neurosurg Psychiatry 37:647–652CrossRefPubMedPubMedCentral

23.

Lee HJ, Bach HJ, DeLisa JA (1992) Lateral dorsal cutaneous branch of the sural nerve. Standardization in nerve conduction study. Am J Phys Med Rehabil 71:318–320CrossRefPubMed

24.

Killian JM, Foreman PJ (2001) Clinical utility of dorsal sural nerve conduction studies. Muscle Nerve 24:817–820CrossRefPubMed

25.

Balci K, Karacayir S, Varol G, Utku U (2005) Utility of dorsal sural nerve in early determination of diabetic polyneuropathy. J Peripher Nerv Syst 10:342–343CrossRefPubMed

26.

Turgut B, Turgut N, Akpinar S, Balci K, Pamuk GE, Tekgunduz E, Demir M (2006) Dorsal sural nerve conduction study in vitamin B(12) deficiency with megaloblastic anemia. J Peripher Nerv Syst 11:247–252CrossRefPubMed

27.

Uluc K, Isak B, Borucu D, Temucin CM, Cetinkaya Y, Koytak PK, Tanridag T, Us O (2008) Medial plantar and dorsal sural nerve conduction studies increase the sensitivity in the detection of neuropathy in diabetic patients. Clin Neurophysiol 119:880–885CrossRefPubMed

28.

Koçer A, Domaç FM, Boylu E, Us Ö, Tanridağ T (2007) A comparison of sural nerve conduction studies in patients with impaired oral glucose tolerance test. Acta Neurol Scand 116:399–405CrossRefPubMed

29.

Turgut N, Karasalihoglu S, Kücükugurluoglu Y, Balci K, Ekuklu G, Tütüncüler F (2004) Clinical utility of dorsal sural nerve conduction studies in healthy and diabetic children. Clin Neurophysiol 115:1452–1456CrossRefPubMed

30.

Dalla Torre C, Zambello R, Cacciavillani M, Campagnolo M, Berno T, Salvalaggio A, de March E, Barilà G, Lico A, Lucchetta M, Ermani M, Briani C (2016) Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study. Neurology 87:1161–1166CrossRefPubMed

31.

Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85:392–398CrossRefPubMed

32.

Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, di Blasio A, Neunhaeuserer D, Zaccaria M, Bergamin M, Ermolao A (2018) Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. Crit Rev Oncol Hematol 121:90–100CrossRefPubMed

33.

Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies ISJ, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Torre CD, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, the CI-PeriNomS Group (2014) Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst 19:127–135CrossRefPubMedPubMedCentral

Title: Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve
Authors: Paola Alberti
Emanuela Rossi
Andreas A. Argyriou
Haralabos P. Kalofonos
Chiara Briani
Mario Cacciavillani
Marta Campagnolo
Jordi Bruna
Roser Velasco
Marina E. Cazzaniga
Diego Cortinovis
Maria G. Valsecchi
Guido Cavaletti
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 9/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4170-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2018

Development of esthetic prosthesis for a patient with severe stigmatizing facial lesions due to cancer: a pilot study

Palliative sedation in advanced cancer patients hospitalized in a specialized palliative care unit

Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours

Patients’ Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS)

A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer